We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 495

Medicare bundled payments initiative and oncology care

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 9 2014

According to Modern Healthcare’s “Interest Surges in Medicare Bundled Payment Initiative” article on July 31, 2014, enthusiasm for bundled pricing

Federal Circuit frames test for patent-eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 8 2014

Personalized medicine relies on diagnostics to analyze a patient for individualized therapy and for monitoring a patient's health status. Some

CMS says: let's make a deal

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 4 2014

In the hours before everyone began enjoying Labor Day Weekend, the Centers for Medicare & Medicaid Services (CMS) issued an important inpatient

7th Circuit defines "worthless services" under the False Claims Act

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 4 2014

That’s the upshot from U.S. ex rel. Absher v. Momence Meadows Nursing Center, Nos. 13-1886 & 13-1936 (Aug. 20, 2014), a recent decision from the

CMS issues Final Rule for inpatient stays in acute care and long term care hospitals

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 3 2014

On August 1, 2014, the Centers for Medicare and Medicaid Services (CMS) issued its annual final rule for policy and payment changes applicable to

CMS issues Final Rule on hospice wage index and payment rate update for FY 2015

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 3 2014

On August 4, 2014, the Centers for Medicare & Medicaid Services (CMS) issued a final rule updating the hospice wage index and payment rate for Fiscal

Considering sex-specific variation for personalized medicine

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

Personalized medicine may use devices and assays that identify sex-related differences. For example, a device or an assay may determine if a cancer

Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

340B Drug Pricing Program interpretative rule survives (for now)

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

A federal court entered a new order, on August 27, 2014, in an ongoing dispute between the Health Resources and Services Administration (HRSA) and

GAO issues report on post-payment claims reviews by CMS contractors

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 28 2014

The U.S. Government Accountability Office (GAO) recently issued a report entitled "Medicare Program Integrity: Increased Oversight and Guidance Could